

## **Genovis Launches AlligBAITOR™ and Strengthens Its Offering in Advanced Protein Analytics**

**Genovis AB today announces the commercial launch of AlligBAITOR™, a novel immunoglobulin-binding protein that expands the company's offering in advanced protein analysis. The product enables capture of all major antibody isotypes and uniquely facilitates the release of antigens from antibody-antigen complexes under native conditions. Together with the high-performance enzymes added through the recent acquisition of KPL, AlligBAITOR strengthens Genovis' proteomics offering by enabling new workflows for the analysis of complex biological samples. The product has already been evaluated by researchers and industry experts across multiple application areas, consistently demonstrating its potential to enable new and improved workflows.**

AlligBAITOR represents a new category of tools within the Genovis portfolio and complements the company's established SmartEnzymes™ platform. Through high-affinity binding to the Fab region of immunoglobulins, the product captures all major antibody isotypes, including IgG, IgA, IgM, and IgE, from complex biological matrices such as human serum.

Unlike traditional antibody-binding proteins such as Protein A and Protein G, which bind only selected antibody classes, AlligBAITOR provides broad isotype coverage. In addition, the product offers a unique capability to release antigens bound to antibodies while preserving their native structure. This opens new possibilities across proteomics, bioanalysis, and diagnostics.

Interest from early access users has been strong across multiple application areas, including proteomics research, bioanalytical characterization, and diagnostic development. The broad application potential is further supported by independent academic validation. A recently published preprint from Professor Albert Heck's group at Utrecht University, one of the world's leading centers in protein mass spectrometry, demonstrates the utility of AlligBAITOR in advanced proteomics workflows and the analysis of complex biological samples.

*"What has impressed me most during the early access phase is the breadth of interest we've seen across very different customer groups. Researchers in proteomics, bioanalysis, and diagnostics have all identified applications relevant to their work. This confirms that AlligBAITOR is not built around a single workflow but rather represents a platform with the potential to enable entirely new analytical strategies,"* says Rolf Lood, VP R&D at Genovis.

AlligBAITOR™ is available in two product formats.

**AlligBAITOR™ Lyophilized** enables pan-Ig capture in solution and can simultaneously release antigens from antibody-antigen complexes under fully native conditions without the use of denaturing reagents. This capability has been demonstrated using clinically relevant antibody-antigen pairs, including trastuzumab-HER2 and adalimumab-TNFα.

**AlligBAITOR™ Affinity Purification** is supplied as ready-to-use microspin columns and enables rapid enrichment or depletion of immunoglobulins from serum. This improves the detection of low-abundance proteins in complex biological samples and creates new opportunities across proteomics, bioanalysis, and diagnostics.

*“AlligBAITOR represents more than a product launch. Together with the proteomics tools added through the acquisition of KPL, the product strengthens our offering in advanced protein analysis and enables integrated workflows for serum and plasma proteomics. By combining immunoglobulin capture, antigen release, and high-performance enzymes in a coordinated solution, we create new opportunities for researchers to analyze complex biological samples and develop next-generation proteomics methods,”* says Fredrik Olsson, CEO of Genovis.

[Read more about AlligBAITOR](#)

#### Contacts

Fredrik Olsson, CEO

Tel: +46 (0)70-276 46 56 [fredrik.olsson@genovis.com](mailto:fredrik.olsson@genovis.com)

#### About Us

Headquartered in Kävlinge, Sweden, Genovis offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Genovis' innovative products and technologies are used by scientists all over the world and the product formats streamline and improve workflows in biochemical analysis and sequencing, as well as in the development, quality control and manufacturing of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiaries Genovis Inc. (US) and SEQURNA AB. Genovis shares are listed on Nasdaq First North Growth Market and DNB Carnegie Investment Bank AB is the Company's Certified Adviser.

*This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.*